J Med Chem
Laboratory for Organic Synthesis, Department of Organic Chemistry, University of Gent, Krijgslaan 281 (S4), B-9000 Gent, Belgium.
Published: September 1999
The synthesis of four CD-ring-modified 19-nor-1alpha, 25-dihydroxyvitamin D(3) derivatives lacking C15, referred to as 6C analogues, and diastereomeric at C17 and C20 is described. The synthesis involves an Ireland-Claisen rearrangement of a 3-methyl-substituted ester of (1R)-3-methyl-2-cyclohexen-1-ol as the key step, followed by elaboration of the side chain, transformation into a C8 cyclohexanone derivative, and final Wittig-Horner coupling with the 19-nor A-ring phosphine oxide. Despite possessing a more flexible side chain than the parent hormone, biological evaluation showed an unexpected superagonistic antiproliferative and prodifferentiating activity (10-50 times higher as compared to that of 1alpha,25(OH)(2)D(3)) for the diastereomer with the "natural" configuration at C17 and C20. The other diastereomers exhibit a 25-90% decrease in activity. All four analogues show a decreased binding affinity (45% or less), and their calcemic activity is 4-400 times less than that of 1alpha,25(OH)(2)D(3). The conformational behavior of their side chain was studied using molecular mechanics calculations, and the result is presented as volume maps. A relative activity volume was determined by subtraction of the volume map of the least active analogue from the volume map of the most active one. This shows three regions corresponding to preferred orientations in space of the side chain of the active analogue. One of these regions was found to overlap with the region that is preferentially occupied by the most active of the four diastereomeric 22-methyl-substituted 1alpha,25(OH)(2)D(3) analogues.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1021/jm980736v | DOI Listing |
Clin Ther
March 2025
Fondazione IRCCS Istituto Neurologico Carlo Besta, Medical Genetics and Neurogenetics Unit, Milan, Italy. Electronic address:
Purpose: The 6 months pilot, single arm, phase I/II, open-label clinical trial PHEMI investigated the safety and efficacy of daily administration of phenylbutyrate in reducing lactic acidosis by at least 20% in 3 children (ages 7-10 yrs) with pyruvate dehydrogenase deficiency and 6 adults with mitochondrial myopathy encephalopathy lactic acidosis and stroke-like episodes. As a side study, we investigated the response to phenylbutyrate treatment in skin fibroblasts and cybrids derived from PHEMI patients with the aim of unraveling a possible in vivo-in vitro correlation.
Methods: Safety was assessed through the collection of vital signs, clinical evaluations, blood samples, and reported adverse events.
Int J Biol Macromol
March 2025
Fiber and Particle Engineering Research Unit, University of Oulu, P.O. Box 4300, 90014 Oulu, Finland. Electronic address:
The heterogeneous structure and characteristic variability of industrial lignin present key challenges that hinder its use in numerous advanced scenarios. Herein, we explore amino acid-derived deep eutectic solvents (AADESs) featuring diverse side chain structures (glycine, alanine, valine, lysine (Lys), and proline) and serving as reactive media for modifying alkali lignin. For the first time, quantum chemistry and molecular dynamics simulations were employed to demonstrate the formation mechanism of AADESs.
View Article and Find Full Text PDFJ Theor Biol
March 2025
Statistical Center for HIV/AIDS Research and Prevention, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, 98101, United States; organization=Stanford Prevention Research Center, organization=Department of Medicine, organization=Stanford University, city=Palo Alto, state=CA, postcode=94304, country=United States. Electronic address:
Pre-exposure prophylaxis (PrEP) is increasingly used to prevent the transmission of H.I.V.
View Article and Find Full Text PDFChembiochem
March 2025
Technische Universität München, Lehrstuhl für Biologische Chemie, Emil-Erlenmeyer-Forum 5, 85354, Freising, GERMANY.
While protein A affinity chromatography is widely established for antibody purification, the acidic elution conditions often lead to protein aggregation and deamidation. Here, we describe an alternative approach for the purification of antibodies utilizing an engineered binding protein based on the archaebacterial Sac7d scaffold in combination with light-controlled α-CD affinity chromatography (Excitography). Starting from a published affitin molecule, we engineered a monomeric protein version (C3A24) by substituting the unpaired thiol side chain Cys24 within the binding site by Ala and, unexpectedly, its binding activity towards the human IgG1 Fc region was even improved (KD = 76 nM).
View Article and Find Full Text PDFFa Yi Xue Za Zhi
December 2024
Shanghai Key Laboratory of Forensic Medicine, Key Laboratory of Forensic Science, Ministry of Justice, Shanghai Forensic Service Platform, Academy of Forensic Science, Shanghai 200063, China.
Objectives: To explore the characteristic fragment ions, ion abundance ratios and mass spectrometry fragmentation rules of etomidate and its structural analogues by using gas chromatography-quadrupole/orbitrap mass spectrometry (GC-Q/Orbitrap MS) and liquid chromatography-linear ion trap quadrupole-orbitrap mass spectrometry (LC-LTQ-Orbitrap MS) techniques, providing important data support for the identification and prediction of etomidate structural analogues.
Methods: GC-Q/Orbitrap MS and LC-LTQ-Orbitrap MS were used to analyze metomidate, etomidate, isopropoxate and propoxate, to obtain their GC high resolution mass spectra and LC high resolution mass spectra.
Results: Under the electron impact (EI) ion source mode, etomidate, metomidate and the other two analogues all produced their molecular ions and seven identical fragment ions ( 77.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!
© LitMetric 2025. All rights reserved.